Chemical Grinding Fluid Market Industry Outline, Global and United States Executive Manufacturers, Interpretation and Benefit Growth 2026 by Fujimi…

Global and United States Chemical Grinding Fluid Market Growth 2020-2026 focuses on the analysis of different factors that augment the markets growth during the anticipated period. The report consists of Chemical Grinding Fluid market dynamics, prospects, starts, market dynamics and even the Global and United States market volumes into account. The report studies the Global and United States status of the market along with growth opportunities, main players and future forecasts.

The segmental analysis offered within the report pinpoints key opportunities on the market within the international Chemical Grinding Fluid market through leading segments. The regional study of the Global and United States Chemical Grinding Fluid market enclosed within the report helps readers to achieve a sound understanding of the event of various geographical markets in recent years and conjointly going forth. Weve provided a close study on the important dynamics of the Global and United States Chemical Grinding Fluid market, that embrace the market influence and market impact factors, drivers, challenges, restraints, trends and prospects.

Access Free Sample Copy of Chemical Grinding Fluid Market Report 2020: https://calibreresearch.com/report/covid19-impact-chemical-grinding-fluid-market-27242#request-sample

The report compiles data on market size, market growth trends that will help its buyer to capture opportunities, to know and minimize probable risks, as well as to analyse the strategies of key companies in the market. The report offers a detailed assessment of the Global and United States Chemical Grinding Fluid market to understand the current trend of the market and figure outs the expected market trend for the market for the forecast period from 2020 to 2026.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

Major Market Manufacturers indulged in this report are:

Cabot MicroelectronicsDow Electronic MaterialsFujimi IncorporatedFujifilmHitachi ChemicalSaint-GobainAsahi GlassAce NanochemUWiZ TechnologyWEC GroupAnji Microelectronics

Chemical Grinding Fluid Market 2020 segments by product types:

Mechanical Action Polishing FluidChemical Action Polishing Fluid

The Application of Global and United States Chemical Grinding Fluid Market 2020-2026 as follows:

Silicon WafersOptical SubstrateDisk Drive ComponentsOther

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert https://calibreresearch.com/report/covid19-impact-chemical-grinding-fluid-market-27242#inquiry-for-buying

The report forecast Global and United States Chemical Grinding Fluid market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2026 due to coronavirus situation. The market report provides a detailed analysis of Global and United States market size, regional and country-level market size, segmentation market growth, market share, competitive landscape, sales analysis, value chain optimization, recent developments, opportunities analysis and strategic market growth analysis. The Global and United States market report covers extensive analysis of emerging trends and competitive landscape. The report explains the flow of the Global and United States Chemical Grinding Fluid supply and demand.

For reader ease, this research presentation on the Global and United States Chemical Grinding Fluid Market recognizes 2019 as the base year and 2020-26 establishes the overall forecast time-line, allowing detailed market approximation about growth likelihood in the Chemical Grinding Fluid Market 2020-2026.

Checkout FREE Report Sample of Chemical Grinding Fluid Market Report for Better Understanding: https://calibreresearch.com/report/covid19-impact-chemical-grinding-fluid-market-27242#request-sample

Our exploration specialists acutely ascertain the numerous aspects of the Global and United States Chemical Grinding Fluid market report. The factors affecting the leading industry players to adopt sourcing of the Global and United States Chemical Grinding Fluid market products have also been studied in this statistical surveying report. The report supplies the study on the insights on cost-effective manufacturing methods, competitive landscape and new avenues for applications.

Read this article:
Chemical Grinding Fluid Market Industry Outline, Global and United States Executive Manufacturers, Interpretation and Benefit Growth 2026 by Fujimi...

Does Spider-Man Have What It Takes To Kill Zombie Mary Jane? – Screen Rant

Spider-Man has the unenviable choice of whether or not to kill his zombified partner, Mary Jane in the latest issue of Marvel Zombies Resurrection.

This article contains spoilers forMarvel Zombies: Resurrection #3

Peter Parker and Mary Jane go together like zombies and decapitation. Or maybe its like peanut butter and jelly, except Spider-Mans peanut butter is an ax and Mary Janes jelly is her head, because Spider-Man may have to kill his zombified life partner.

Spider-Man has been aiding Reed and Sue Richards children in their quest to find a cure to the infection that has turned all superheroes - and the remaining human population that hasnt already become food - into zombies. Thezombie disease came from Galactus corpse, which crash landed on earth and its revealed in Marvel Zombies: Resurrection #3 that the infected can travel the multiverse via portals into Limbo thanks to a zombified Magik. As Spider-Mans crew of zombie killers/would-be infection healers arrive at the hives central location in the underwater city of Atlantis, they are surrounded by a legion of zombie superheroes and none other than the love of Peter Parkers life.

Related: Marvel's Deadliest Version of Punisher Joins The Zombie Apocalypse

Now undead, Mary Jane offers immortality to Spider-Man via infection. Creative team Phillip Kennedy Johnson and Leonard Kirk offer up an unenvious choice to Peter Parker: kill M.J. or turn into a zombie. The everlasting life of a zombie could seem a romantic notion to Peter, who could spend eternity with his partner. An immortality marred by the grim prospect of killing to eat and watching his girl devour everyone in sight, but immortality nonetheless.

Peter has spent every issue of this seriesrevisiting his past mistakes through horrid nightmares that play out at the beginning of each comic. In his flashbacks, Spider-Man relives the early days of the infection. Most heroes fell quickly and Spider-Man was stuck caring for Valeria and Franklin Richards after their parents turned. He couldnt kill Reed and Sue then but he certainly wasnt going to let the kids join the family business of brain eating. But now faced with the option to finally stop running and living in constant fear, does Spider-man have what it takes to kill?

Spider-Man is one of the more altruistic heroes and has often sacrificed himself for the greater good. But there is no greater good option here; its just kill or turn. Spider-Man and Mary Jane are meant for each other, but does that love extend into the afterlife? Will Spider-Man be able to stomach the remains of dead flesh as well as the regretful choice of turning zombie to be with his love? It seems unlikely that Spider-Man would give up his mortal life to be with M.J. when he still has the Richards kids to keep care of. Though it surely has to be tempting.

The alternatives to becoming a zombie are not ideal. Spider-Man and his cohorts are surrounded by super-powered undead and are trapped in the sunken city of Atlantis. Its down to fight, flight or become a feast for the undead fiends. The limited series is set to wrap up with the next issue, so Spider-Mans impossible choice will probably lead up to the conclusion of the story. And in a series rife with bleak choices it only makes sense that Spider-Man is faced with the ultimate one.

The rest is here:
Does Spider-Man Have What It Takes To Kill Zombie Mary Jane? - Screen Rant

Confronting The Dead In The Actun Tunichil Muknal Cave In Belize – TravelAwaits

The sheer number of pots, dark and brown pottery of all sizes, was staggering. Early explorers say more than 1,400 pots were found just laying in plain sight in the flowstone pools, visible to the naked eye with no need for excavation. Thousands more are likely buried under layers of calcite, each one begging Chac for rain, rain, please bring the rain.

We all slinked along the ridges of the pool, inches away from artifacts that had survived for centuries in the dark.

Look down, said Ian.

It took me a second to realize I was staring down at a skull, its yellowed jaw missing its two front teeth like some cheerful toddler. Several years before, a photographers long lens knocked the teeth out as he bent over too far for that perfect picture.

Above and past the ladder of doom, another skull laid face down. A large hole in the back of the skull made me think this soul was bludgeoned, but I was wrong.

A man, holding his own and his wifes digital camera, had struggled for a couple of shots, and he accidentally dropped his wifes camera, which burst through the cranium.

For the powers that be in Belize, that was nearly the last straw. Terrified of the continued damage to the relics and remains, the government planned to close the cave, but the official guides begged and pleaded, and a compromise was made.

No photos. No cameras. No gear. So far, that rule has worked, and no other major incidents of damage have occurred since, Ian said.

This is our livelihood, he said. We fought to keep the cave open for tours. We go through a long training to become guides. Its an honor.

Staring at my crystallized boy, it was an honor for me to be in the dark with him, to remember him in some small way for what he gave up to try to save his people.

His death wasnt enough for Chac. The rains didnt come. Massive cities were left abandoned for the jungle to reclaim, and his people scattered defeated and lost across Belize, Honduras, Guatemala, and Mexico.

But still, The Crystal Maiden remains silent and still and glowing under the eyes of tourists curious for a glimpse of immortality. For me, the dangers of the underworld were worth the chance to slip back into history and honor the dead.

Original post:
Confronting The Dead In The Actun Tunichil Muknal Cave In Belize - TravelAwaits

50 years old | Ainos daughter has been the most demanding coworker of illustrator Ville Tietvinen Nothing suited her without negotiation – Pledge…

The conscious does not believe that anything digital will last very long.

Cartoon artist and illustrator Ville Tietvinen turns 50, but his thoughts revolve on three time levels within a radius of 5,000 years, from the Bronze Age to the present.

Iiro Kttnerin scripted cartoon work Spacing is nearing completion.

Its based on the earliest found Aramaic scroll that tells a version of a 5,000-year-old flood story, Tietvinen says.

An archaeological detective story in modern times explores what really happened in the days of Noah and how history was rewritten in 450 BC when book scrolls were burned in the Jerusalem temple.

Spacing will be released next fall. Knowledgeable and known as a screenwriter, Kttner has used the University of Helsinkis Old Testament Exegesis Lecturer as an expert. Kirsi Valkamaatawho, according to Tietvinen, knows the Bronze Age very well.

The Dead Sea the scrolls have made the Knowledgeable think modern digital. There are still mostly parts of them, but something has survived.

SpacingWhen making the book, the belief in anything permanent has faltered. But if anything about us survives, then books. I dont think anything digital will last very long. I cling to analog and as old ways as possible to tell new stories.

Culture and art have traditionally been seen to represent the mortal mans desire for immortality, a means to leave a mark on the world of itself.

Immortality was also discussed by the photographer Maija Tammen made with Immortal (2020), a combination of art and non-fiction. It tells of a Hydra polyp that does not age and could live forever unless external factors kill it.

Known with Kttner has done the same Tree stories trilogy, picture books for adults. Thinning was supposed to be the next part of the series, but the Knowledgeable liked the idea by asking Kttner to expand the comic script from it.

About thinning becomes more than 140 pages long, the most extensive work of the conscious then Invisible hands comic book work (2011).

The book about a paperless Moroccan immigrant received tremendous publicity, was taken in four editions, and translated into German, French, Swedish, and Arabic.

Invisible hands i did five years, drawing took three years. Thinning Ive done a couple of years. A cartoon is a cumbersome way of telling stories, so its not worth using for day flies. But I miss that dialogue of image and word.

Knowledgeable especially to draw his comics in a laborious, almost as laborious style as his illustrations. Many cartoonists use lighter techniques.

Invisible hands after the conscious artistic burden has been lightened by collaborators, Kttner and Tammi, but also Aino Tietvinen, his own daughter, with whom Tietvinen made a book mixing comics and picture books Just a bad dream (2013) Ainos dreams.

I thought I was a perfectionist, but Maija was interested in all the steps of making a book. It is enjoyable to work with Iiro because he knows everything about the structures of the stories and is therefore able to break them.

But Aino has definitely been the most demanding partner. Nothing suited him without negotiation. But I had to illustrate his imagination.

At the time of writing, Aino Tietvinen was 67 years old.

Ville Tietvinen became interested in making comics only as an adult, while studying. He studied architecture. First-born Smiling moon (1995) was born then Harri Hannulan with.

We started making the best cartoon in the world. Now I hope the publisher has rejected it. I graduated as an architect, but I havent done those jobs in a single day. I am not formally valid for anything I do.

In addition to his own books, Tietvinen has made layouts, stamps, posters and more for other books. After comics, he is best known for magazine illustrations. He has done journalistic illustration Ville Hnninen with book Narrative image (2018).

Even in illustrating magazines, the Knowledgeable is more fascinated by paper than the web, even though he uses digital aids in drawing. He says the golden age of newspaper illustration is ten years behind. Before, more than half of Knights work was in it, now about a quarter.

Illustration can deepen the news in a different way than photography, but the savings have struck and it is being used less all the time. Images increase but content does not. It is claimed that we live in visual time, but this does not always seem to be the case.

Who?

Born in Helsinki in 1970.

Graduated as an architect from the Helsinki University of Technology in 2000.

Illustrations from the 1990s to Helsingin Sanomat, Yliopisto magazine and Suomen Kuvalehti, among others.

Comic books: Smiling Moon (1995), Birds and Seas (2003), Invisible Hands (2011), Only Bad Dream (2013).

Storybook series Trees of Trees (20142015) with Iiro Kttner.

Picture book Invisible (2016) with Elina Hirvonen.

Narrative image non-fiction book (2018) on journalistic illustration with Ville Hnninen.

Art book Immortal Lost Memoirs of Cornelia Dulac Concerning the Freshwater Polyp Hydra (2020) with Maija Tammi.

Awards include: Finnish Critics Associations Criticism Incentives for Birds and the Sea 2004, Finnish Cultural Foundations Invisible Hands Award 2011.

Turns 50 on Tuesday 20.10.

.

Originally posted here:
50 years old | Ainos daughter has been the most demanding coworker of illustrator Ville Tietvinen Nothing suited her without negotiation - Pledge...

Requiem For A Theme: Film Composer Clint Mansell On The Sound Of Sadness – Delaware First Media

The 2000 film Requiem for a Dream celebrates its 20th anniversary this fall, and in that time there's at least one part of its legacy that's never faded: the music. The movie's haunted original score spawned a kind of breakout hit that would ripple through media for years to come, while also kickstarting a new career for its British-born composer, Clint Mansell.

Mansell churned out a whole batch of disparate musical ideas after reading the script for the film, which director Darren Aronofsky co-adapted with Hubert Selby Jr. from the 1978 novel of the same name, about four characters succumbing to addiction. The sketch that became the score's central theme, Mansell remembers, was track 17 out of 20 on a demo CD he'd made, and sounded like kind of a hip-hop slow jam: "It even had sort of an 808 beat under it," he says. It didn't yet have the stabbing melody line that would become its hallmark; for now it was just three sad, descending chords.

Aronofsky had originally asked Mansell to write a hip-hop score for the story, since that was the music of the Brooklyn director's youth, but Mansell kept getting stuck. He was on the verge of quitting when Aronofsky flew to New Orleans where Mansell was living in an apartment owned by and adjacent to Trent Reznor for a desperate session of just throwing ideas from the CD against scenes in the film. They randomly tried the theme track under a scene where the character Marion (Jennifer Connelly), who has just slept with her therapist for drug money, stumbles out into a violent thunderstorm and vomits. "And it was just like, oh my God, what's this?" Mansell says. "It was one of those magical moments where image plus music creates this third element."

He developed that seedling into a piece called "Lux Aeterna," and it became the core idea of the score, an addictive uroboros of despair that was further elevated by the artistry of Kronos Quartet, who performed it for the recording. "It's not just the chords, it's not just the melody," Mansell says of the track's essential power, "it's the life that [Kronos] breathed into it." The theme plays in slightly different variations throughout the film during the speed-fueled montage of Sara (Ellen Burstyn) cleaning her apartment, or when Tyrone (Marlon Wayans) flees a drug dealer's limo after a violent shootout and it crescendos in the finale as the four main characters each curl up into a fetal position. "Darren had said, 'It's like a horror movie, really. Every time that the addiction wins, that's a win for the monster,' " Mansell recalls. " 'Lux Aeterna' is basically a monster theme."

Requiem was only the composer's second film score, and he says he felt way out of his depth. A self-taught guitar player from the industrial town of Stourbridge, 100 miles north of London, Mansell formed the band Pop Will Eat Itself when he was 19. The group's sample-heavy style a mashup of post-punk, rock and hip-hop was dubbed "grebo." They didn't garner any big hits, but "like the best music of that time, you felt like you were in a club," Reznor says. "If you saw other people at that rack in the record store, or wearing a t-shirt, you shared some common insight and secret society vibe. [The band] felt like a refreshing breath of truth. It wasn't concerned about political correctness or anything else. It just felt like an interesting collage of music and presentation. It just felt alive."

Reznor liked PWEI so much that he signed the band to his label, Nothing Records. He says that in his New Orleans base of operations at the time, "We had a big studio with a lot of rooms for people to hang out, and it also had two separate apartments attached to the building. At some point, after we had toured together and Clint and I had become friends and drinking buddies and kind of comrades, I vaguely remember he was in some form of crisis in his life, and was living in New York and needed to get away. And I said, 'Well, there's an apartment here. Anytime, you know indefinitely if you want to stay there, there's nobody living there.' "

Mansell was transitioning out of PWEI, and had just written an electronic score for Aronofsky's first feature, Pi. He moved into one of the apartments, and Reznor bought him his first Apple computer and Pro Tools setup. "I remember him working super hard, and my recollection is it taking quite a bit of time, and just hearing peripherally about the frustrations and the learning curve but a real excitement," he says. "And to my amazement, this incredible film pops out, with this incredible soundtrack. I was really happy for him. And suddenly he's a big film composer."

Though Reznor says Mansell didn't directly inspire his own evolution into a film composer 10 years later with The Social Network, he adds: "Clint would have given me the confidence to feel like it could be done. You know, it's not an impossible thing. He's proven you can do that, without 20 years of university studies and degrees."

Requiem for a Dream premiered at the Cannes Film Festival in May 2000, and was released in theaters that December. Burstyn received an Oscar nomination for her performance as an aging woman in unglamorous descent, but the film a relentlessly bleak, hallucinogenic trip that crescendos into a symphony of debasement wasn't exactly a smash. Aronofsky chose to release it unrated to avoid an NC-17 rating, which all but relegated it to art houses.

Likewise, the "monster theme" for this controversial, indie downer should have faded into obscurity. Instead, it quietly became a monster hit not on the radio, but relentlessly licensed in other media. Most of that can be traced to its usage in the theatrical trailer for The Lord of the Rings: The Two Towers in 2002, where it was given an "epic" remix, goosed with a warlike choir and full orchestra, which was created specially for the trailer by Simone Benyacar, Daniel Nielsen and Veigar Margeirsson.

After that, the "Requiem for a Tower" remix kept getting used in movie trailers including for The Da Vinci Code, I Am Legend and Sunshine as well as for video games (Assassin's Creed), advertising campaigns (Canon cameras, Molson Canadiaan beer) and on TV shows (The Late Show with David Letterman, So You Think You Can Dance). Mansell wasn't paid much up front for the score, but he held onto the writing and publishing rights. Each licensing fee would have brought in somewhere between $35,000 and $100,000. "If I could do that every day, you know, fantastic," he says, laughing.

Mansell's film scoring career ignited after Requiem. He scored four more films for Aronofsky, including Noah, the Grammy-nominated Black Swan -- where he applied a remix approach to the music of Tchaikovsky and The Fountain, about a man whose wife is dying of cancer and his desperate quest for immortality. It had been discovering David Bowie that turned a young Mansell onto music in the 1970s; in 2009, Bowie's son Duncan Jones found himself using the scores from Requiem and The Fountain as reference tracks for his sci-fi thinker, Moon so he asked Mansell to score it.

Moon and Requiem became favorites of another director, Ben Wheatley, leading him and Mansell to collaborate on 2015's High-Rise and, most recently, a new adaptation of the Daphne du Maurier classic Rebecca for Netflix. "The thing that I love about his music in general," Wheatley says, "is the sorrow, the sadness of things. As light and as romantic as it can sound, there is always that underscore, undertow, of sadness. And I definitely feel that is totally appropriate for [Rebecca,], because the story is sad about things."

In 2014, sorrow paid a personal visit to Mansell: His girlfriend, actress Heather Mottola, died of complications from pneumonia at just 29. The last thing they'd seen in a theater together was a concert film of Lou Reed performing his polarizing album Berlin.

"Obviously I was grieving, and in a lot of shock," Mansell says. "It was traumatic. I did therapy and grief counseling, and they all kind of pointed at the idea that, 'You should express yourself through music, and do something musical for her.' " He ultimately decided to make a track-for-track cover album of Berlin, which he released this summer.

Even though Reed's subject matter is grim drugs, murder, doomed romance Mansell and his collaborator, Clint Walsh, decided to make it in the glam punk style that Mottola loved. "The reinterpretation of the music actually became about us doing it, not what it represented," he says. "We had fun making that record. The original record is very downbeat, and it's bleak. I think we found some hope in our version."

Mansell's collaborators tend to say he's a pretty cheery and funny guy, who happens to be drawn to stories in the realm of requiems. "But I think it's more than that," Mansell says for his own part. "I think it's to do with the authenticity of those things, you know, and the stakes of them. They're just the ones that feel real to me, that musically bring something out of me. I want to spend the time with them you know? It feels important to me."

See original here:
Requiem For A Theme: Film Composer Clint Mansell On The Sound Of Sadness - Delaware First Media

X-Men: X of Swords Pushes Mr. Sinister Into a Battle With His Own Clone – Screen Rant

In the latest issue of Hellions, Mr. Sinister has the perfect plan to avoid responsibility and danger in X of Swords... or so he thinks.

Warning: spoilers ahead for Hellions #5

Marvel's "X of Swords"event is well underway for the X-Men's island nation of Krakoa, as its ten mutant champions have gone out to collect their blades for the coming tournament against Arakko, with the winner claiming Krakoa as the prize. This is all being orchestrated by Lady Saturnyne, the regent of Otherworld, whose realm stands between Krakoa and its long lost sibling nation of Arakko, which has been taken over by the forces of Apocalypse's children. While Krakoa's Quiet Council deliberates, one of their members, Mr. Sinister, comes up with a plan to stop the coming conflict before it even starts. However, he gets more than he bargained for by proposing this plan, motivating Sinister to do something quite drastic (with hilarious results).

Mr. Sinister's amazing plan is quite sinister (surprise, surprise), but possibly very effective. Sinister wants to send his team of Hellions to Otherworld to try and steal the swordsthat Arakko's champions are searching for, thereby forcing a forfeit and precluding the need for any bloodshed or loss of life, as the mutants' ability to resurrect has been disabled. As a result, the Council reaches a majority vote to send the Hellions on a mission to fulfill Sinister's plan. However, the Council also votes to send Sinister along as well to lead his team, something that he was not expecting or wanting at all. With the Council having spoken, Mr. Sinister has no choice but to go to Otherworld and risk death. Or does he?

Related:X-Men Theory: X of Swords Will End With a Sinister Betrayal

After meeting with the Council, Sinister returns to Bar Sinister, his resident base of operations on Krakoa. Almost immediately, he thaws out one of his clones to go instead inHellions #5,written by Zeb Wells with art by Carmen Carnero. However, a clone of Sinister is still Sinister, personality and all, so why should he go when he just woke up? Caught in a stalemate with himself, the two Sinisters do the only thing they can to resolve the issue: The Noble Contest.

Of course, readers have no clue which Sinister won the "noble contest" of Rock, Paper, Scissors, though part of the fun of this interaction is that they don't really need to. Furthermore, it totally makes sense that Sinister would have his own secret and illegal cloning facility off the books, as his experiments towards creating Chimera mutantsare no doubt already underway. Plus, it comes in handy to always have a decoy and means of immortality. Even if he ends up being the one who has to risk his life, at least he can be confident that he'll live on with the next clone.

Link:
X-Men: X of Swords Pushes Mr. Sinister Into a Battle With His Own Clone - Screen Rant

Altered Carbon fans need to do this after watching show – Looper

Altered Carbon is based on the 2002 novel of the same name by author Richard K. Morgan. That book is followed by the sequels Broken Angels and Woken Furies. Although there will always be the requisite book versus adaptation arguments, the Altered Carbon fan base appears to be happy with Morgan's series.

In a Reddit threadentitled "Are the books worth it?," u/IssueAcrobatic starts the conversation by writing, "So Altered Carbon s1 is probably my favorite piece of cinematic work ever, the world and the concepts are just f***ing perfect. I love Kovac' [sic] character and all of the small really well thought out details (Kovac [sic] poisoning himself to lower his body temp and get past a scanner) and stuff like that. My question is, are the books good? Are they worth a read?"

Suffice it to say, other users would agree that the books are, in fact, worth the read. "The books are amazing," another user responded. "So gritty and visceral. Richard Morgan is an all around amazing author." In case fans of the show still aren't convinced, another user said, "All the books are worth reading. They're all really good. The world is more fleshed out and there are plenty of those little details. The books handle Envoys better than the show. Kovacs feels way more op."

As can be expected, the TV show contains some different elements than the book series. Another user mentions, "The biggest difference is Quell and Quellism it's a completely different philosophy in the books and I think the show makes it worse. Also, the Envoy Corps are not the Quellist Black Brigades in the books, they are an elite version of Protectorate forces."

While there are other differences such as the Elders already being extinct in the booksas opposed to the last remaining Elder appearing in the second season of the TV series fans appear to appreciate the literature just as much as the show, if not more.

View original post here:
Altered Carbon fans need to do this after watching show - Looper

Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging…

The Healthcare Nanotechnology (Nanomedicine) market report offers a comprehensive and in-detail assessment of the Healthcare Nanotechnology (Nanomedicine) market and focuses on the key growth contributors of the market to gain a knowledgeable insight on the market. The report contains a detailed account of the history of the Healthcare Nanotechnology (Nanomedicine) market and a thorough and detailed forecast up to the year 2026.

The report takes into account the important factors and aspects that are crucial to the client to post good growth and establish themselves in the Healthcare Nanotechnology (Nanomedicine) market. Aspects such as sales, revenue, market size, mergers, acquisitions, risks, demands, new trends, threats, opportunities, and much more are taken into account to procure a detailed and descriptive research report on the Healthcare Nanotechnology (Nanomedicine) market.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/36794

Description:

This report offers segmented data categorized as per related segments of the Healthcare Nanotechnology (Nanomedicine) market and as the international markets change, the report has documented all the essential aspects that affect the overall growth curve of the market. The reports cover all the segments extensively and offer a detailed explanation of all the factors crucial to growth.

The given report has been assessed to give maximum benefit to our clients and to establish them among the frontrunners in the Healthcare Nanotechnology (Nanomedicine) market. The report has been compiled by using various analyses that have proven to be a game-changer for many in the Healthcare Nanotechnology (Nanomedicine) market. The research sources and tools used by our analysts to assess the report are highly reliable and trustworthy and are approved by industry experts.

The following players are covered in this report:

Amgen

Teva Pharmaceuticals

Abbott

UCB

Roche

Celgene

Sanofi

Merck & Co

Biogen

Stryker

Gilead Sciences

Pfizer

3M Company

Johnson & Johnson

SmitH& Nephew

Leadiant Biosciences

Kyowa Hakko Kirin

Takeda

Ipsen

Endo International

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/36794

Competitive Analysis:

The report offers effective guidelines and recommendations for players to secure a position of strength and dominance in the Healthcare Nanotechnology (Nanomedicine) market. The report offers extensive coverage of the competition and has a detailed account of the mergers, acquisitions in the Healthcare Nanotechnology (Nanomedicine) market landscape.

The report includes comprehensive data on mergers and acquisitions that will help the clients to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Breakdown Data by Type

Nanomedicine

Nano Medical Devices

Nano Diagnosis

Other

Healthcare Nanotechnology (Nanomedicine) Breakdown Data by Application

Anticancer

CNS Product

Anti-infective

Other

Based on regional and country-level analysis, the Healthcare Nanotechnology (Nanomedicine) market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

Have Any Query ask to our Expert @ https://beathanreports.com/get-expert-help/36794

Reasons to buy:

See more here:
Healthcare Nanotechnology (Nanomedicine) Market: Analysis and In-depth Study on Healthcare Nanotechnology (Nanomedicine) Market Size Trends, Emerging...

Dr. Amy Liao Receives the Wallace A. Coulter Award for Healthcare Innovation – PRNewswire

CHELMSFORD, Mass., Oct. 16, 2020 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq: BRKS) announced today that Dr. Amy Liao, president of Brooks Life Science Services, has received the Biomedical Engineering Society's Wallace A. Coulter award for innovation in healthcare. The Coulter award recognizes an outstanding individual who has demonstrated a lifetime commitment to and made important contributions to patient healthcare. Dr. Liao will be speaking at the plenary session of the 2020 Biomedical Engineering Society's virtual meeting on Friday October 16, 2020.

"We are very proud to see Amy recognized by the Biomedical Engineering Society with this award," commented Steve Schwartz, CEO and president of Brooks Automation. "Amy's accomplishments with over 20 years in the field of genomics has led to breakthrough innovations in gene sequencing and gene synthesis, and in GENEWIZ, she built a company that has supported thousands of customers in their pursuit of scientific discoveries. All of us at Brooks congratulate Amy for this recognition of her achievements."

Dr. Amy Liao was appointed President of Brooks Life Sciences Services in April 2020. She joined Brooks in November 2018 following its acquisition of GENEWIZ, a global provider of genomics services, which she co-founded in 1999. Dr. Liao held various leadership positions during her tenure at GENEWIZ culminating in her appointment as Chief Executive Officer in January 2017. Dr. Liao received her Ph.D. in Biochemistry and Cell Biology from SUNY Stony Brook. She did her post doctorate studies at Columbia University before leaving to found GENEWIZ. She holds a B.S. in Biochemistry from Nankai University, China and an M.S. in Biochemistry from Tsinghua University, China.

About Brooks AutomationBrooks (Nasdaq: BRKS) is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide. The Company's Life Sciences business provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Brooks Life Sciences' GENEWIZ division is a leading provider of DNA gene sequencing and gene synthesis services. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks is a provider of industry-leading precision vacuum robotics, integrated automation systems and contamination control solutions to the world's leading semiconductor chip makers and equipment manufacturers. Brooks is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, visit http://www.brooks.com.

INVESTOR and MEDIA CONTACT:

Mark NamaroffDirector, Investor RelationsBrooks Automation 978.262.2635[emailprotected]

SOURCE Brooks Automation

http://www.brooks.com

Excerpt from:
Dr. Amy Liao Receives the Wallace A. Coulter Award for Healthcare Innovation - PRNewswire

Global Biochemical Reagents Market Offered in New Research Forecasted through 2025 – Express Journal

Growth Forecast Report on Biochemical Reagents Market Size | Industry Segment by Applications (Hospitals, Diagnostic centers and Academics and Research), by Type (Polymerase chain reaction (PCR) reagent kits, Cell and tissue culture reagents, Electrophoresis reagents, Chromatography reagents and Others), Regional Outlook, Market Demand, Latest Trends, Biochemical Reagents Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts to 2025. Analyzes current market size and upcoming 5 years growth of this industry.

The research report on Biochemical Reagents market report consists of a thorough assessment of this industry domain. As per the study, the market is expected to acquire notable returns and showcase a healthy growth rate during the forecast period.

The document investigates the major industry trends and elaborates on the volume of sales, market size, growth opportunities, and revenue estimations. The report provides a succinct analysis of growth avenues and also elaborates market segmentations.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/224585

Also, the research report evaluates the impact of COVID-19 pandemic on the growth propellers of the Biochemical Reagents market.

Other takeaways of the Biochemical Reagents market report:

As per the regional analysis of the Biochemical Reagents market:

The report comprises of a granular analysis of the geographical landscape of the Biochemical Reagents market and divides the same into:

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Biochemical Reagents Industry product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Biochemical Reagents market, with price, sales, revenue and global market share of Biochemical Reagents Industry in 2018 and 2019.

Chapter 3, the Biochemical Reagents market competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Biochemical Reagents market breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.

Chapter 12, Biochemical Reagents market forecast, by regions, purity and application, with sales and revenue, from 2020 to 2025.

Chapter 13, 14 and 15, to describe Biochemical Reagents market sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/224585

Read this article:
Global Biochemical Reagents Market Offered in New Research Forecasted through 2025 - Express Journal

COVID-19 Impact ON Biochemical Reagent Market Manufacturers Analysis And Industry Insights 2020-2026 | Thermo Fisher Scientific, Beckman Coulter,…

Global Biochemical Reagent market forecast 2020-2026 tracks the latest market dynamics, such as driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. It provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries.

The Biochemical Reagent market size reports can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Biochemical Reagent market industry.

Get a Sample Copy of the report:https://www.reporthive.com/request_sample/2469931

Major players covered in this report:

Thermo Fisher ScientificBeckman CoulterAbbottMerck & Co., Inc.Life TechnologiesBio-RadWater CorporationSigma-AldrichAgilent Technologies Inc.Betcon DickinsonRocheAB AnaliticaGesan ProductionMedicalsystem Biotechnology Co., Ltd.PromegaPZ CorAugustSENTINEL CH.Teco DiagnosticsDickinson & Company

Biochemical Reagent market by Types:

Chromatography ReagentsElectrophoresis ReagentsMass SpectrometryPCR Reagent KitsCell and Tissue Culture Reagents

Biochemical Reagent market by Applications:

Protein Synthesis and PurificationGene ExpressionDNA and RNA AnalysisDrug Testing

Inquire or share your questions if any before the purchasing this report @https://www.reporthive.com/request_customization/2469931

Geographically, the regional consumption and value analysis by types, applications, and countries are included in the report. Furthermore, it also introduces the major competitive players in these regions.

Major regions covered in the report:-North America-Europe-Asia-Pacific-Latin America-Middle East & Africa

Detailed TOC of Global Biochemical Reagent market:1 Market Overview1.1Biochemical Reagent market Introduction1.2 Market Analysis by Type1.2.1 Type 11.2.2 Type 21.3 Market Analysis by Application1.3.1 Application 11.3.2 Application 21.4 Market Analysis by Region1.4.1 United States Market States and Outlook (2014-2026F)1.4.2 Europe Market States and Outlook (2014-2026F)1.4.3 China Market States and Outlook (2014-2026F)1.4.4 Japan Market States and Outlook (2014-2026F)1.4.5 Southeast Asia Market States and Outlook (2014-2026F)1.5 Market Dynamics and Development1.5.1 Merger, Acquisition and New Investment1.5.2 Market SWOT Analysis1.5.3 Drivers1.5.4 Limitations1.5.5 Opportunities and Development Trends1.6 Global Market Size Analysis from 2014 to 20261.6.1 Global Market Size Analysis from 2014 to 2026 by Consumption Volume1.6.2 Global Market Size Analysis from 2014 to 2026 by Value1.6.3 Global Price Trends Analysis from 2014 to 20262 Global Biochemical Reagent market Competition by Types, Applications, and Top Regions and Countries2.1 Global Biochemical Reagent market(Volume and Value) by Type2.1.1 Global Biochemical Reagent market Consumption and Market Share by Type (2014-2019)2.1.2 Global Biochemical Reagent market Revenue and Market Share by Type (2014-2019)2.2 Global Biochemical Reagent market(Volume and Value) by Application2.2.1 Global Biochemical Reagent market Consumption and Market Share by Application (2014-2019)2.2.2 Global Biochemical Reagent market Revenue and Market Share by Application (2014-2019)2.3 Global Biochemical Reagent market(Volume and Value) by Region2.3.1 Global Biochemical Reagent market Consumption and Market Share by Region (2014-2019)2.3.2 Global Biochemical Reagent market Revenue and Market Share by Region (2014-2019)

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Read the original:
COVID-19 Impact ON Biochemical Reagent Market Manufacturers Analysis And Industry Insights 2020-2026 | Thermo Fisher Scientific, Beckman Coulter,...

Teen on the mend after colitis battle – Prince George Citizen

After being diagnosed with ulcerative colitis at seven years old, one local teenager is happily in remission after years of treatment.

The journey to get to that point wasn't an easy one and required help from many sources.

Kalena needed specialized treatment that included attending at BC Children's Hospital several times a year.

Kathy Samaai, Kalena's mom, said it was a scary time for the family when Kalena was first diagnosed on her seventh birthday.

Ulcerative colitis is rarely diagnosed in someone her age.

The trouble started about six months before the diagnosis when Kalena started getting fevers for no apparent reason. She was in pain and began having bloody stool that prompted her family to take her to the local emergency room on a regular bases.

Kalena was only six years old and needed specialized tests like an endoscopy and a colonoscopy.

Those procedures are not done in Prince George in children and the she needed to go to Vancouver.

"Its a 12-hour drive, Samaai said. Our car wasnt new and I was working full time and worried about missing work.

Once diagnosed the proposed treatment options were not ideal and while one involved an invasive surgery that involved installing a stoma bag that sits outside the body, the other was a biochemical infusion that comes with risk of side effects.

"Kalena always liked to swim, especially synchronized swimming and just loves the water so wearing a bag was not ideal," Samaai said.

As a family it was decided that the biochemical infusions would be used for treatment, as long as Kalena's system would accept it.

"But of course with the biochemical comes side effects like a sensitivity to sun, for example," Samaai said. "So she had to stay out of the sun or cover up really well to avoid burning because that could lead to cancer."

The treatment was administered at BC Children's Hospital and would continue every eight weeks for the foreseeable future.

The trips by car down south were all right until winter hit and that was when hospital staff told Samaai about Hope Air to help with flights to and from treatments.

When I called Hope Air it was a good experience, Samaai said, The staff was easy to connect with and our flight was booked. That was in 2012 and we have been flying with Hope Air ever since. We just couldnt have done it without Hope Air.

Before that first trip. Kalena had never even been on a plane. She and her mother have made 75 trips with Hope Air to date.

Kalena is now 16, currently in remission and feeling good.

She is a volleyball player and a swimmer working on getting her lifeguard certification. Kalena wants to go into medicine when she's older and once the coronavirus pandemic is over she looks forward to life guarding to earn money for her tuition.

Read the original post:
Teen on the mend after colitis battle - Prince George Citizen

Rutgers Awarded $5 Million Grant from NIH to Improve Access to COVID-19 Testing within Underserved and Vulnerable Communities – Rutgers Today

The award is part of the RADx Underserved Populations (RADx-UP) program in the Rapid Acceleration of Diagnostics (RADx) initiative

The New Jersey Alliance for Clinical and Translational Science (NJ ACTS) at Rutgers University received a $5 million National Institutes of Health grant to launch outreach campaigns and expand access to COVID-19 testing for underserved and vulnerable communities in New Jersey.

The grant will fund a Rutgers-led study called the New Jersey Healthcare Essential WoRker Outreach and Education Study - Testing Overlooked Occupations, or NJ HEROES TOO, under the NIHs Rapid Acceleration of Diagnostics (RADx) initiative, RADx Underserved Populations (RADx-UP) program. The program supports research that aims to better understand COVID-19 testing patterns among underserved and vulnerable populations; strengthen the data on disparities in infection rates, disease progression and outcomes; and develop strategies to reduce the disparities in COVID-19 testing.

NJ HEROES TOO focuses on the Black and Latinx communities disproportionately affected by COVID-19 in places where Rutgers academic medical centers are deeply rooted. NJ ACTS partnered with community and health care organizations in Essex, Middlesex, Passaic and Union counties to co-design this study.

Medical sociologist and lead principal investigator for the study, Shawna Hudson, who is also co-director of Community Engagement forNJ ACTS, reflected that much of the public attention with frontline health care heroes has been focused on doctors and nurses. NJ HEROES TOO focuses on vulnerable health care workers and their families, including home health and personal care aides, maintenance staff, housekeeping, and hospital security, groups which are largely Black and Latinx and have concerns about exposing their families, friends and communities.

This is an incredible opportunity to improve COVID-19 awareness in vulnerable individuals across NJ. Its a game changer, said Reynold Panettieri, director of NJ ACTS.

Rutgers is one of 32 institutions that received an NIH award through the RADx-UP program to support projects designed to rapidly implement COVID-19 testing strategies in populations disproportionately affected by the pandemic. These groups include African Americans, American Indians/Alaskan Natives, Latinos/Latinas, Native Hawaiians, older adults, pregnant women, and those who are homeless or incarcerated.

It is critical that all Americans have access to rapid, accurate diagnostics for COVID-19, especially underserved and vulnerable populations who are bearing the brunt of this disease, said NIH director Francis S. Collins. The RADx-UP program will help us better understand and alleviate the barriers to testing for those most vulnerable and reduce the burden of this disease.

Rutgers researchers are also working with community organizations to understand the best way of communicating the importance of being tested and facilitating COVID-19 at-home saliva self-testing.

We need to recognize the disparities for Black and Latinx communities. To help address inequities, it is critical that we use an on-the-ground approach by partnering with community members whom they know and trust. We need to ensure that the people and families who need testing and treatment are detected earlier and get help earlier, added Manny Jimnez,a study principal investigator and director of developmental and behavioral pediatrics education at the Boggs Center on Developmental Disabilities at Rutgers Robert Wood Johnson Medical School.

NJ HEROES TOO will be developed in two phases. The first phase includes an evaluation process involving stakeholder interviews, evidence-based content review, pilot testing, and stakeholder input to inform design and implementation of outreach strategies. The second phase will examine the impact of the studys outreach strategies on health care workers, their family members and the broader community.

The study brings together researchers, health care and community partners in a collaborative effort, and is led by the following six principal investigators:

Health care and community organizations participating include: Parker Health Group; Visiting Nurse Association Health Group; ASPIRA Association; Central Jersey Family Health Consortium, Inc.; East Orange Senior Volunteer Corporation; Health Coalition of Passaic County; Mobile Family Success Center; New Brunswick Area Branch NAACP; New Brunswick Tomorrow; New Hope NOW Community Development Corporation; Partnership for Maternal and Child Health of Northern New Jersey; Program for Parents; Puerto Rican Action Board (PRAB); The Bridge; Township of Hillside Senior Recreation Center; United Way of Greater Union County; and Urban League of Union County.

Continued here:
Rutgers Awarded $5 Million Grant from NIH to Improve Access to COVID-19 Testing within Underserved and Vulnerable Communities - Rutgers Today

Co-Occurrence of the mcr-1.1 and mcr-3.7 Genes in a Multidrug-Resistan | IDR – Dove Medical Press

Chongtao Du,1,* Yuyang Feng,1,* Guizhen Wang,2 Zhiyuan Zhang,1 Huimin Hu,1 Yu Yu,1 Jiayang Liu,1 Lihao Qiu,1 Hongtao Liu,1 Zhimin Guo,3 Jing Huang,3 Jiazhang Qiu1

1Key Laboratory of Zoonosis, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun 130062, Peoples Republic of China; 2College of Food Engineering, Jilin Engineering Normal University, Changchun 130052, Peoples Republic of China; 3Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun 130021, Peoples Republic of China

*These authors contributed equally to this work

Correspondence: Jiazhang QiuCollege of Veterinary Medicine, Jilin University, No. 5333 Xian Road, Changchun 130062, Peoples Republic of ChinaEmail qiujz@jlu.edu.cnJing HuangDepartment of Clinical Laboratory, The First Hospital of Jilin University, Changchun 130021, Peoples Republic of ChinaEmail huangj@jlu.edu.cn

Objective: A colistin-resistant Escherichia coli strain isolated from dog feces was characterized in this study.Methods and Results: A multiplex PCR assay was used to detect the presence of colistin-resistant mcr genes; it was found that E. coli QDFD216 co-harbored the mcr-1 and mcr-3 genes. Whole-genome sequencing and further bioinformatics analysis revealed that E. coli QDFD216 belonged to serotype O176:H11, fimH1311 type and ST132. The resistance genes blaCTX-M-14, mdfA, dfrA3, acrA, acrB, tolc, and sul3 were present in the chromosome. The mcr-1.1 and mcr-3.7 genes were located in two plasmids of different incompatibility groups. mcr-1.1 was carried by a IncX4-type plasmid within an typical IS 26-parA-mcr-1.1-pap2 cassette, while mcr-3.7 was encoded by an IncP1-type plasmid with a genetic structure of TnAs2-mcr-3.7-dgkA-IS 26. No additional antibiotic resistance genes were carried by either plasmid.Conclusion: This is the first report of an E. coli isolate co-harboring a mcr-1.1-carrying IncX4 plasmid and a mcr-3.7-carrying IncP1 plasmid. The evolution and mechanism of mcr gene co-existence need further study to assess its impact on public health.

Keywords: colistin resistance, whole-genome sequencing, mcr genes, mcr-1, mcr-3

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Follow this link:
Co-Occurrence of the mcr-1.1 and mcr-3.7 Genes in a Multidrug-Resistan | IDR - Dove Medical Press

FDA officials, experts discuss impact of COVID-19 on cell and gene therapies – Regulatory Focus

While the US Food and Drug Administration (FDA) is still receiving investigational new drug applications (INDs) for cell and gene therapies, officials are concerned about the impact of the COVID-19 pandemic on clinical trials.Its clear that COVID-19 has adversely affected all aspects of development of cell and gene therapies, said Peter Marks, director of FDAs Center for Biologics Evaluation and Research (CBER), said at the Alliance for Regenerative Medicines Meeting on the Mesa. For some of the studies that are ongoing there are some real challenges to overcome in terms of endpoints that may have been missed.The pandemic also has disrupted global harmonization efforts around gene therapies, Marks said.We were on the cusp, in fact, working with global regulators trying to get towards more harmonization of gene therapy programs in different countries, he said. Were trying to keep it moving but its a challenge to do.Marks noted that before COVID-19 he spent about 75% of his time on cell and gene therapies, but the pandemic has forced him to shift priorities. Some things have less policy demands at this point in time. At this point in time its very much reversed and its probably 80% of my time on COVID-related activities.Marks also noted that CBERs Office of Tissues and Advanced Therapies (OTAT) has been struggling to keep up with its workload even before the pandemic. With the influx of applications for cell and gene therapies over the last five years, Marks said the office, Should have doubled in size and its only modestly larger, 15-20% larger in size.Marks said he is not satisfied with the level of dialogue the agency has been able to have with gene therapy developers. Especially early on, we should be able to have this dialogue that really facilitates setting things up well so that our knowledge of the entire fieldwe help leverage that for every sponsor.Weve been so strapped in terms of personnel that its hard to do that, Marks said, noting that COVID-19 has exacerbated things even further. Because the number of gene therapy applications hasnt fallen off dramatically, some of the trials may not be moving as quickly, but the applications keep coming in. Marks said that OTAT has also had to shift priorities during the pandemic and that he hopes the next user fee cycle will bring in the resources necessary to staff up further.Speaking on a separate panel with members of industry, OTAT Director Wilson Bryan echoed Marks sentiment.We were stretched thin before the pandemic, and with the flood of work that came in, it really had an impact, he said. Sometimes folks dont like to admit this, but we all know weve had delayed meetings, weve had to delay review of some applications because of giving priority to the pandemic.However, Bryan said the office is getting its balance and is working to catch up on some of its delayed activities.Bryan expressed some worry about the financial well-being of some of the smaller companies his office works with. Were hearing a lot about their struggles to stay afloat and continue and finish off their development programs and whether or not those development programs are going to be sufficient to meet regulatory standards, he said.One of the challenges, said Timothy Schroeder, CEO of CTI Clinical Trial & Consulting, will be dealing with gaps in data from clinical trials. The question is going to be how do sponsors, how do regulatory authorities and how do companies such as ourselves fill those gaps?On the regulator side, Bryan said his office is working with companies on an individual basis to sort out those issues, which differ from one indication to the next.Bryan added that one positive to come of the pandemic is greater interest in remote outcome assessments in clinical trials. If we have an energy now to develop outcome measures and validate outcome measures that allow us to reliably capture information from patients in remote locations, that will ultimately facilitate development, he said.The pandemic also has significantly disrupted FDAs ability to conduct surveillance and preapproval inspections. While the agency has resumed some domestic inspections and mission-critical foreign inspections, it also is leveraging other sources of information, including inspection reports from other regulators, and requesting documents from applicants and facilities in lieu of on-site inspections where possible. (RELATED: FDA issues pandemic inspections FAQ guidance, Regulatory Focus 19 August 2020).Were considering virtual inspections, particularly for companies where the site has a track record, but if its a site that is brand new with no track record or if its a site with that has a bad track record, were hesitant to do that, Bryan said.Bryan also raised the prospect of FDA inspectors tagging along remotely for an inspection being conducted by other regulators. Is it possible that we could have an inspection by European inspectors and have US regulators going along for a virtual inspection at the same time? We think about those things, I dont know that weve done them yet, Bryan said, adding that he is not sure whether FDA inspectors would be comfortable with the information they would get.Curran Simpson, chief operations and technology officer at REGENXBIO, said he sees promise in virtual audits and believes the level of documentation a site provides can be indicative of its compliance.How often have I walked into a manufacturing facility thats well-run but has terrible documentation? Almost never. I think virtual audits, if you do a risk-based approach and the audit partner has the ability to send documentation in an efficient way and you have experienced people doing this, I think youre going to get the same flavor of an audit very quickly from the level of the documentation, he said.Of course, youll want to accompany that to the extent possible with imaging of the facility, Curran said, To see if those practices are being followed, the overall cleanliness of the facility and the management of material movement If you dont get a good impression from the documentation that youre working through, its probably a bigger issue that you want to escalate.Amy DuRoss, co-founder and CEO of Vineti, an enterprise software company specializing in advanced therapies, expressed some doubts about the current potential for fully remote audits.Certainly our piece of the chain because were enterprise software is readily auditable remotely, but I would say that the overall system and in manufacturing, Im not sure weve evolved as a species yet to adapt our remote techniques to get a full picture I dont think were there yet, she said.

Read this article:
FDA officials, experts discuss impact of COVID-19 on cell and gene therapies - Regulatory Focus

Identification of Novel Therapeutic Molecular Targets in Inflammatory | CEG – Dove Medical Press

Sachin Mohan,1 3 Shaffer Mok,4 Thomas Judge5

1Department of Gastroenterology and Hepatology, University of Minnesota School of Medicine, St Paul, MN, USA; 2Regions Hospital, Department of Gastroenterology and Hepatology, St Paul, MN, USA; 3Health Partners Digestive Care Center, St Paul, MN, 55130, USA; 4Division of Gastroenterology and Hepatology, University Hospital Digestive Health Institute, Westlake, OH 44145, USA; 5Division of Gastroenterology and Liver Diseases, Cooper University Hospital, Mount Laurel, NJ 08054, USA

Correspondence: Sachin MohanRegions Hospital, Department of Gastroenterology and Hepatology, 435 Phalen Blvd, St Paul, MN 55130, USATel +1 651-254-8680Fax +1 651-254-8656Email sachinmohan01@gmail.com

Purpose: Utilization of genetic databases to identify genes involved in ulcerative colitis (UC), Crohns disease (CD), and their extra-intestinal manifestations.Methods: Protein coding genes involved in ulcerative colitis (3783 genes), Crohns disease (3980 genes), uveitis (1043 genes), arthritis (5583 genes), primary sclerosing cholangitis (PSC) (1313 genes), and pyoderma gangrenosum (119 genes) were categorized using four genetic databases. These include Genecards: The Human Gene Database (www.genecards.org), DisGeNET (https://www.disgenet.org/), The Comparative Toxicogenomics Database (http://ctdbase.org/) and the Universal Protein Resource (https://www.uniprot.org/). NDex, Network Data Exchange (http://www.ndexbio.org/), was then utilized for mapping a unique signal pathway from the identified shared genes involved in the above disease processes.Results: We have detected a unique array of 20 genes with the highest probability of overlay in UC, CD, uveitis, arthritis, pyoderma gangrenosum, and PSC. Figure 1 represents the interactome of these 20 protein coding genes. Of note, unique immune modulators in different disease processes are also noted. Interleukin-25 (IL-25) and monensin-resistant homolog 2 (MON-2) are only noted in UC, CD, pyoderma gangrenosum, and arthritis. Arachidonate 5-lipoxygenase (ALOX5) is involved in UC, CD, and arthritis. SLCO1B3 is exclusively involved with pyoderma gangrenosum, UC, and CD. As expected, TNF involvement is noted in CD, UC, PSC, and arthritis. Table 1 depicts the detailed result.Conclusion: Our work has identified a distinctive set of genes involved in IBD and its associated extra-intestinal disease processes. These genes play crucial roles in mechanisms of immune response, inflammation, and apoptosis and further our understanding of this complex disease process. We postulate that these genes play a critical role at intersecting pathways involved in inflammatory bowel disease, and these novel molecules, their upstream and downstream effectors, are potential targets for future therapeutic agents.

Keywords: inflammatory bowel diseases, IBD, ulcerative colitis, UC, Crohns disease, CD, arthritis, primary sclerosing cholangitis, PSC, uveitis, pyoderma gangrenosum

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Identification of Novel Therapeutic Molecular Targets in Inflammatory | CEG - Dove Medical Press

Detailed analysis of the competitive landscape in the Global Cell Therapy Manufacturing Market by 2030 – Eurowire

The approval of KYMRIAH, YESCARTA, Alofisel and Zyntelgo has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity

Roots Analysis has announced the addition of Cell Therapy Manufacturing Market (3rd Edition), 2019 2030 report to its list of offerings.

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry.

To order this 500+ page report, which features 160+ figures and 250+ tables, please visit this link

More than 160 organizations claim to be engaged in cell therapy manufacturingThe market landscape is dominated by industry players, representing more than 60% of the total number of stakeholders. Amongst these, over 55 are large or mid-sized firms (having more than 50 employees).

100+ players focused on T-cell and stem cell therapiesMost of these players are focused on manufacturing T-cell therapies, including CART, TCR or TILs. It is worth highlighting that more than 35 organizations claim to have necessary capabilities for the manufacturing of both types of therapies.

Presently, 70+ companies have commercial scale capacityAs majority of the cell therapy products are in clinical trials, the demand is high at this scale. However, it is worth noting that several players (~50%) have already developed commercial scale capacity for cell therapies.

Europe is currently considered a current hub for cell therapy productionMore than 220 manufacturing facilities have been established by various players, worldwide; of these, 35% are in Europe, followed by those based in North America. Other emerging regions include Australia, China, Japan, Singapore, South Korea and Israel.

50+ facility expansions reported between 2015-2019More than 85% of the expansions are related to setting up of new facilities across different regions. Maximum expansion activity was observed in the US and in certain countries within the Asia Pacific regions.

20+ companies offer automated solutions to cell therapy developersPlayers that claim to offer consultancy services related to automation include (in alphabetical order) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics, GE Healthcare and Terumo BCT. Further, we identified players, namely (in alphabetical order) Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Invetech, KMC Systems, Mayo Clinic Center for Regenerative Medicine and RoosterBio, that offer consultancy solutions related to automation.

Partnership activity has grown at an annualized rate of 16%, between 2014 and 2018More than 200 agreements have been inked in the last 5 years; majority of these were focused on the supply of cell-based therapy products for clinical trials. Other popular types of collaboration models include manufacturing process development agreements (16%), services agreements (12%) and acquisitions (10%).

By 2030, developed geographies will capture over 60% of the market shareAsia Pacific is anticipated to capture the major share (~36%) of the market by 2030. It is also important to highlight that financial resources, technical expertise and established infrastructure is likely to drive cell therapy manufacturing market in Europe, which is estimated to grow at a CAGR of ~26%.

To request a sample copy / brochure of this report, please visit this link

The USD 10+ billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:

The research covers profiles of key players (industry and non-industry) that offer manufacturing services for cell-based therapies, featuring a company overview, information on manufacturing facilities, and recent collaborations.

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html or email [emailprotected]

You may also be interested in the following titles:

Contact:Gaurav Chaudhary+1 (415) 800 3415+44 (122) 391 1091[emailprotected]

See the original post:
Detailed analysis of the competitive landscape in the Global Cell Therapy Manufacturing Market by 2030 - Eurowire

IBCN 2020: IBCN 2020: Molecular Correlates of Cisplatin-Based Chemotherapy Response In Muscle-Invasive Blad… – UroToday

(UroToday.com) While cisplatin-based chemotherapy is a mainstay for neoadjuvant and adjuvant treatment of patients with muscle-invasive bladder cancer (MIBC), and none of the reported biomarkers for predicting response have been implemented in the clinic thus far.

Dr. Ann Taber presented data from researchers at the Aarhus University Hospital, Denmark, where they performed comprehensive genomic, transcriptomic, epigenomic, and proteomic analysis of 300 MIBC patients treated with cisplatin-based chemotherapy to identify molecular changes associated with treatment response. Based on mutational signatures, they identified two patient groups: those characterized by mutations in a tri-nucleotide signature 5 context (SBS5) that are related to ERCC2 mutations, and those related to APOBEC mutations.

Expression data identified the basal/squamous gene expression subtype to be associated with poor cisplatin-based treatment response. Immune cell infiltration and high PD-1 protein expression was also significantly associated with treatment response; they identified a unique subset that corresponds to an immune desert, which was associated with poor treatment response (Figure 1).

Figure 1: Association of immune cell infiltration and cisplatin-based treatment response.

The authors then assigned patients to high and low genomic instability groups based on SBS5 mutations, indels, allelic imbalance and BRCA2 mutation status. Patients with high genomic instability had a response rate of 71% versus 49% for patients with low genomic instability (p = 0.007). Through further integration, they identified a group of patients with a very high response rate (80%) characterized by high genomic instability and non-basal/squamous gene expression subtype and a group of patients with a very low response rate (25%) characterized by low genomic instability and basal/squamous gene expression subtype (p<0.001, Figure 2).

Figure 2: Patient subclassification based on genomic instability and basal/squamous gene expression subtype.

The results highlight several molecular correlates of chemotherapy response. These findings are now the basis of a new clinical trial for the treatment of metastatic bladder cancer following radical cystectomy.1

Presented by: Ann Taber, Ph.D., Department of Molecular Medicine (MOMA), Aarhus University Hospital, Denmark.

Written by:Anirban P. Mitra, MD, Ph.D., Urologic Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Twitter: @APMitra, with Ashish M. Kamat, MD, MBBS, President of IBCN and IBCG, Endowed Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Twitter:@UroDocAsh,at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.

References:1. Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy (TOMBOLA). ClinicalTrials.gov identifier NCT04138628.

Visit link:
IBCN 2020: IBCN 2020: Molecular Correlates of Cisplatin-Based Chemotherapy Response In Muscle-Invasive Blad... - UroToday

IBCN 2020: Improving Immune Checkpoint Inhibitor Therapy In Cancer – UroToday

(UroToday.com)Application of immune checkpoint inhibitor (ICI) therapy has seen significant progress in the last few years. Agents targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1 have shown activity in locally advanced and metastatic urothelial carcinoma in the first- and second-line setting.1,2 However, a significant proportion of patients still perform poorly after receiving these therapies as their disease progresses rapidly.

In his keynote presentation at the 2020International Bladder Cancer Network (IBCN) Annual Meeting, Dr. Dan Theodorescu challenged the audience to seek alternative approaches to tackle this problem. He suggested that this may be addressed by either discovery of new therapies, or using novel modalities to enhance the effect of current ICI therapies. His research group has, more recently, focused on the latter approach.

While the idea of combination therapy has been successfully applied for chemotherapeutic regimens, an existing problem is that agnostic drug combinations could result in the need for far too many dual-drug clinical trials that would just not be feasible in the current environment. He, therefore, pointed out that an urgent need, therefore, is to rationally choose drugs that would be potentially optimal combinations with immune checkpoint inhibitors. The underlying goal of his groups current investigations is to identify molecular pathways that allow cancer growth while on ICI, and identify drugs that can target such pathways to enhance ICI response (Figure 1). His group has employed functional genomics to identify such lethal combinations.

Figure 1: Using functional genomics to identify rational combinations with ICI.

He elaborated on the technique for the construction of such functional genomic druggable libraries, wherein gene targets of drugs used in clinical trials for bladder cancer were identified, and five shRNAs per gene were constructed as part of a lentiviral library that were used to infect murine bladder cancer cells. The best performing shRNAs were selected as models for inhibiting the respective pathways and used to test in combination with ICI therapy. Using this approach, and in combination with anti PD-1 therapies, tumors that were resistant to the latter therapy were profiled using next-generation sequencing to identify pathways of ICI escape (Figure 2).

Figure 2: Identifying synthetic lethal combinations with anti PD-1

These investigations identified DDR2 and CCL2 alterations as key escape mechanisms. The DDR2 gene encodes for discoidin domain-containing receptor 2, a receptor tyrosine kinase that can be targeted by dasatinib.3 His group, therefore, proceeded to characterize DDR2 alterations in the context of ICI therapy in bladder cancer.4 Their analysis of published bladder cancer genomic profiling data indicated that patients with high DDR2 were associated with worse survival in four independent cohorts. When bladder cancer cells were transduced with DDR2 shRNAs in vitro, this resulted in appropriate reduction in protein levels (Figure 3). In the presence of anti PID-1, there was a significant reduction in subcutaneous tumor growth in syngeneic mice with bladder tumors that also stably expressed shDDR2, indicating a synergistic response. A similar response was also observed in melanoma and breast cancer in vivo models.

Figure 3: Effect of DDR2 depletion on anti PD-1 response.

RNA from mice bearing shControl and shDDR2-transduced bladder tumors treated with antiPD-1 were analyzed using RNAseq followed by gene set enrichment analysis. This revealed a strong immune response in the shDDR2 tumors treated with anti-PD-1 when compared with controls. Cytometry by time-of-flight analysis of these tumors revealed increased CD8+ T cell infiltration into shDDR2 tumors treated with anti-PD-1, which was not seen in the spleen. These observations suggested a strong T cell presence following the treatment of shDDR2-treated tumors with anti-PD-1.

To further evaluate the efficacy of targeting DDR2, the combination of dasatinib and anti-PD-1 was tested. Whereas therapeutic blockade of PD-1 or DDR2 alone had little or no effect on murine bladder tumors, treatment with the combination of dasatinib and anti-PD-1 showed a significant reduction in tumor burden (Figure 4). Similar results were seen within vivo colon cancer and sarcoma models.

Figure 4: Effect of dasatinib on PD-1 response.

Similar studies of synthetic lethal combinations of anti-PD-1 with CCL2 inhibitors are now underway in Dr. Theodorescus lab. Unpublished data from his group indicates that the combination of CCL2 depletion with anti-PD-1 has a significant effect in metastatic melanoma. The data indicate there may be potential benefits in considering triple-drug combinations that target DDR2, CCL2 and PD-1.

In closing, Dr. Theodorescu highlighted recent developing results from a Phase II trial of sitravatinib, a multi-receptor tyrosine kinase inhibitor in combination with nivolumab that is indicating encouraging clinical activity in checkpoint inhibitor nave, platinum-experienced patients with advanced or metastatic urothelial carcinoma.5 The combination with data generated from his lab and early trial results suggest that there is merit in the addition of targeted therapeutics with ICI for treatment of advanced bladder cancer.

Presented by: Dan Theodorescu, MD, Ph.D., Director of the Cedar-Sinai Cancer Center, Phase ONE Distinguished Endowed Chair in Cancer Research, Professor of the Departments of Surgery, Pathology and Laboratory Medicine, Cedars-Sinai Health System, Los Angeles, CA, USA.

References:1. Powles T, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncol 2017;3(9):e172411.2. Sharma P, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312-322.3. Carafoli F, Hohenester E. Collagen recognition and transmembrane signalling by discoidin domain receptors. Biochim Biophys Acta 2013;183:2187-94.4. Tu MM, et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv 2019;5(2):eaav2437.5. Msaouel P, et al. 705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) nave, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Annals Oncol 2020;31(4):S556.

Written by:Anirban P. Mitra, MD, Ph.D., Urologic Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Twitter: @APMitra, with Ashish M. Kamat, MD, MBBS, President of IBCN and IBCG, Endowed Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Twitter:@UroDocAsh,at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.

See original here:
IBCN 2020: Improving Immune Checkpoint Inhibitor Therapy In Cancer - UroToday

FAA cuts the red tape for commercial rocket launches (and landings, too) – Space.com

Commercial space is about to become more accessible than ever before.

Today (Oct. 15), the U.S. Federal Aviation Administration's (FAA) Office of Commercial Space Transportation (AST) announced that it has published a new launch and re-entry rule known as the Streamlined Launch and Re-entry Licensing Regulation-2 (SLR2). The new rule aims to increase launch and reentry access for commercial space companies while maintaining safety.

"We've seen the first launch of American astronauts into orbit aboard an American-built rocket since the end of the space shuttle program ... to the International Space Station," United States Secretary of Transportation Elaine Chao, said in a news conference today, referring to SpaceX's two-month Demo-2 mission, which lifted off on May 30.

"Our country is headed towards a record year in commercial space, and our goal in finalizing this new regulation is to keep it that way," Chao said.

"We're cutting the red tape that has held this industry to the launch pad for far too long," FAA assistant administrator for communications Brianna Manzelli said at the news conference.

Related: Trump's Space Policy Directive 2 could make life easier for SpaceX & others

This new rule is rolled out under the President's Space Policy Directive-2 (SPD-2), which was enacted in 2018. SPD-2 guides the Secretary of Transportation to create a new regulatory structure for launch and re-entry activities. The directive also advises the Secretary to consider allowing commercial operations to launch and re-enter Earth's atmosphere with just a single license (as opposed to having to get a new license for individual activities).

And with SLR2, the FAA has done just that. Now, only a single license is required "for all types of commercial space flight launch and re-entry operations," according to SLR2, which "increases flexibility for launch and re-entry vehicle operations."

With SLR2, the FAA aims to streamline launch and re-entry procedures, so, "while it is laser-focused on public safety, it only regulates to the extent necessary," Wayne Monteith, the FAA's associate administrator for commercial space transportation, said during the news conference today. "The goal is to simplify the licensing process and a lot of novel operations, reduce costs and positioning both the industry and the FAA for the rapid increase in the number of launches that are coming, all without compromising safety."

One interesting component of this new regulation sort of gets rid of the old rules that stated that the license for a launch would "begin" or take effect upon arrival at the launch site for example, the gate at Cape Canaveral Air Force Station in Florida.

Instead, now, "an individual company can, in essence, negotiate with us when they want the license to begin," Monteith said. "It reduces [the] burden on the individual stakeholder. And it certainly reduces [the] burden on government to monitor operations that have little to no impact on public safety."

Email Chelsea Gohd at cgohd@space.com or follow her on Twitter @chelsea_gohd. Follow us on Twitter @Spacedotcom and on Facebook.

See the original post here:

FAA cuts the red tape for commercial rocket launches (and landings, too) - Space.com